25 results about "Deoxycholic acid" patented technology

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the content of deoxycholic acid injection. The detection method employs high-performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. The HPLC chromatographic conditions are as follows: the column is an octadecylsilane-bonded silica column; the column dimensions are 4.6 × 150 mm, and the packing diameter is 3 μm; the detection wavelength is 220 nm; the mobile phase is 0.1% formic acid aqueous solution – 0.1% formic acid acetonitrile solution (42:58). Compared with existing technologies, UV detectors are more readily available than CAD detectors. This invention achieves quantitative detection of deoxycholic acid injection content by controlling the HPLC conditions of the UV detector. This method exhibits baseline stability, good specificity, accuracy, and precision, and is of significant importance for the quality control of deoxycholic acid injection.

This invention belongs to the field of traditional Chinese medicine technology, and provides the application of Scutellaria baicalensis leaf aqueous extract in the preparation of drugs for improving or treating inflammatory bowel disease (IBD) with depression. The Scutellaria baicalensis leaf aqueous extract improves IBD with depression by increasing the abundance of Akkermansia myxophilus (AKK) bacteria, restoring disordered deoxycholic acid metabolism. The extract increases the abundance of AKK bacteria in the intestine, increases the content of deoxycholic acid (DCA) in the intestine, regulates Th17 / Treg homeostasis, reduces intestinal inflammation, maintains intestinal barrier integrity, reduces the entry of pro-inflammatory factors into the bloodstream and across the blood-brain barrier into the hippocampus, inhibits neuroinflammation, and improves depression. Scutellaria baicalensis leaves can improve IBD with depression by increasing the abundance of AKK bacteria in the intestine, increasing intestinal DCA levels, regulating Th17 / Treg balance, repairing the intestinal barrier, reducing LPS leakage and alleviating nerve damage, and inhibiting the inflammatory response of the gut-brain axis. This provides certain experimental evidence for the development and utilization of related traditional Chinese medicine resources.

The application discloses a 7beta-hydroxysteroid dehydrogenase mutant and application thereof, relates to the field of bioengineering technology, and is designed and reformed according to the amino acid sequence of wild-type 7beta-hydroxysteroid dehydrogenase derived from Collinsella aerofaciens, that is, 17 single-mutation sites or 7 combined-mutation sites of 7beta-hydroxysteroid dehydrogenase are provided, the obtained 7beta-hydroxysteroid dehydrogenase mutant has the thermal stability increased by 2-21.5 DEG C and the activity increased by nearly 1.2-2.24 times compared with the wild-type 7beta-hydroxysteroid dehydrogenase. According to the mutation sites with obvious increase in thermal stability and activity, three preferred mutant proteins are further provided, the three preferred mutant proteins have higher yield, activity and thermal stability compared with the wild-type 7beta-hydroxysteroid dehydrogenase, have wider application conditions, are more suitable for the efficient production of ursodeoxycholic acid by the bioconversion method, and are favorable for large-scale production and industrial application.

The application discloses a deoxycholic acid intermediate and application thereof, and belongs to the technical field of organic synthesis. The deoxycholic acid intermediate has a structural formula as shown in the specification, wherein R1 is -OH or -OAc; R2 is alpha-OH, beta-OH or =O; and R3 is =O or -CHCH3. In addition, the application further provides application of the deoxycholic acid intermediate in preparation of deoxycholic acid. The intermediate can be used for effectively and safely synthesizing deoxycholic acid.

This invention provides a 7α-HSDH enzyme mutant and a 7β-HSDH enzyme mutant, their encoding genes, and their applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

A method for treating or reducing localized fat, and a pharmaceutical composition for use in treating or reducing localized fat. The method comprises injecting the pharmaceutical composition into the localized fat of a subject in need, wherein the pharmaceutical composition comprises deoxycholic acid and a viscous agent, and wherein deoxycholic acid is present in the pharmaceutical composition in an amount of 1% to 5% w / v.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

A method for treating or reducing localized fat, and a pharmaceutical composition for use in treating or reducing localized fat. The method comprises injecting the pharmaceutical composition into the localized fat of a subject in need, wherein the pharmaceutical composition comprises deoxycholic acid and a viscous agent, and wherein deoxycholic acid is present in the pharmaceutical composition in an amount of 1% to 5% w / v.

This invention provides the application of deoxycholic acid in the treatment of postherpetic neuralgia. This invention is the first to discover that deoxycholic acid is effective in treating postherpetic neuralgia, and that inhibiting the nucleus tractus solitarius-paraventricular nucleus circuit of the thalamus is also effective in treating postherpetic neuralgia. A synergistic therapeutic effect was achieved when deoxycholic acid was combined with an inhibitor of the nucleus tractus solitarius-paraventricular nucleus circuit. This invention provides a new strategy for the treatment of postherpetic neuralgia.

The present invention relates to a composition comprising (1) a cyclic peptide or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and (2) ursodeoxycholic acid or a pharmaceutically acceptable salt thereof.

The application provides a synthesis method of deoxycholic acid (DCA). The method takes phytosterol as a starting material, and synthesizes deoxycholic acid (DCA) through a series of steps such as primary alcohol oxidation reaction, witting reaction, hydrogenation reaction, selective reduction reaction, hydroxyl protection reaction, elimination reaction, allyl oxidation reaction and hydrolysis reaction. The synthesis method has high reaction yield and high product purity, the intermediates in each step are all solid, easy to purify, the post-treatment method is simple, the cost is low, suitable for quality control, convenient for industrialized production, and has a good application prospect. Moreover, the deoxycholic acid (DCA) synthesized by the method also avoids the risk of containing animal pathogens and other harmful factors.

This invention relates to the pharmaceutical field, specifically disclosing the application of bile acids in the preparation of drugs for treating osteoporosis. Studies have found that the content of porcine deoxycholic acid (HDCA) is significantly reduced in older individuals, and that HDCA supplementation can improve bone mineral density and bone microstructure. Animal experiments show that oral gavage of HDCA can significantly inhibit bone loss and improve bone quality, with its effect dependent on the bile acid receptor TGR5. This invention is the first to propose HDCA as an active ingredient for treating osteoporosis, providing a new drug candidate and mechanism of action for the prevention and treatment of osteoporosis.

Methods for stereoselectively crystallizing 3-keto-5β-cholanic acid (“3-KCA”) and 3-ketoursodeoxycholic acid (“3-KUDCA”) of extremely high purity, salts for carrying out such methods, particularly tert-butylamine and cyclohexylamine salts of 3-KCA, tert-butylamine salts of 3-KUDCA, and crystalline forms of these salts, as well as methods for preparing commercial steroid compounds from these purified materials.

This invention discloses the application of porcine bile acid components in the preparation of drugs for treating irritable bowel syndrome (IBS-D). The study found that the content of porcine bile acid components in the peripheral feces of IBS-D patients treated with traditional Chinese medicine was significantly increased. Furthermore, compared with a healthy control group, the content of porcine bile acid components in the peripheral fecal samples of IBS-D patients was significantly reduced. Further research revealed that porcine deoxycholic acid and natural traditional Chinese medicine porcine bile powder can significantly improve diarrhea and abdominal pain symptoms in TNBS-induced mice by inhibiting tryptophan hydroxylase 1 activity and reducing peripheral serotonin levels. This invention suggests the application value of porcine bile acid components in the treatment of IBS-D.

The application discloses a complex of ursodeoxycholic acid or obeticholic acid and teprenone and application of the complex in preparation of a medicine for preventing and treating liver fibrosis. The combination of ursodeoxycholic acid or obeticholic acid and teprenone can significantly reduce the levels and contents of glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST) and hydroxyproline (Hyp) in model mice, thereby the effect of ursodeoxycholic acid or obeticholic acid in treating liver fibrosis can be enhanced. Therefore, the complex of ursodeoxycholic acid or obeticholic acid and teprenone has a potential for preventing and treating liver fibrosis, which is superior to ursodeoxycholic acid or obeticholic acid single component.

This invention belongs to the field of veterinary pharmacy and relates to the application of chenodeoxycholic acid (CDCA) in the preparation of drugs for treating canine acute pancreatitis. This invention is the first to propose the application of CDCA in the preparation of drugs for treating canine acute pancreatitis, clarifying that it achieves therapeutic effects by reducing pancreatic CT values, alleviating pancreatic edema and necrosis, and improving pancreatic tissue pathological damage, providing a novel strategy and drug option for targeted treatment of canine acute pancreatitis.

The utility model relates to the technical field of pharmaceutical engineering, disclose goose deoxycholic acid crystallization integrated device, including crystallization kettle, the upper surface of crystallization kettle is connected with the crystallization kettle cover plate slidingly, the inner wall of crystallization kettle cover plate is fixedly connected with telescopic water pipe, the upper surface of crystallization kettle cover plate is fixedly connected with flange shaft sleeve, the upper surface of flange shaft sleeve is fixedly connected with connecting plate, the upper surface of connecting plate is fixedly connected with motor, the output of motor is fixedly connected with bearing, the lower surface of bearing is fixedly connected with shaft body, the output of motor is fixedly connected with paddle, the inside of crystallization kettle is provided with cleaning mechanism, in the utility model, through telescopic pipe spherical shower nozzle, telescopic rod is used as water inlet valve connection shower nozzle part, can directly to the bottom of device work, the spherical shower nozzle can be without dead angle spray in the crystallization kettle inner wall cleaning fluid, and the problem of not easy to clean is improved.

This invention provides a method for preparing an intermediate of ursodeoxycholic acid. The method includes asymmetric reduction hydrogenation of a compound of formula VI to obtain a compound of formula VII. The purity and content of the isomers of the obtained product are significantly improved, providing a new method for chiral control in the preparation of ursodeoxycholic acid. This invention also provides a method for preparing ursodeoxycholic acid from dichlorol via asymmetric reduction and other reactions. This method has advantages such as readily available raw materials from plant-derived fermentation, low cost, short reaction time, high product purity, and high yield, making it suitable for industrial production.

This invention discloses a 7α-hydroxysteroid dehydrogenase derived from animal fecal metagenomics, its preparation method, and its applications, belonging to the field of genetic engineering technology. The amino acid sequence of the enzyme is shown in SEQ ID NO.2, and the nucleotide sequence encoding the enzyme is shown in SEQ ID NO.1. The enzyme has a specific activity of 444.15 ± 41.38 U / mg, an optimal temperature of 50℃, an optimal pH of 10.0, and retains over 90% of its activity after 12 hours of incubation at pH 10.0. It exhibits good alkali tolerance. EDTA enhances enzyme activity, while Ag+ and SDS completely inactivate the enzyme. This enzyme has broad substrate specificity, catalyzing the conversion of chenodeoxycholic acid to 7-keto-lithocholic acid, providing a highly efficient candidate enzyme for the biosynthesis of ursodeoxycholic acid, and has significant application value in the medical field.

The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of which are derived solely from plant sources.